Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPiCS-03: Sacituzumab Govitecan in Metastatic Solid Tumors
NCT03964727Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Oct 2019
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of sacituzumab govitecan in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), endometrial cancer (EC) and 1 more (6 cohorts), sponsored by Gilead Sciences. Primary endpoint: Objective Response Rate up to 5.3 years. Started Oct 2019; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)endometrial cancer (EC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03964727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03964727.